Role of Transposable Elements in Septic Immune Aging (SITE)

University of California San Francisco (UCSF)

Status: Enrolling

Conditions: Sepsis at Intensive Care Unit; Sepsis and Septic Shock; Sepsis With Multiple Organ Dysfunction (MOD); Sepsis, Severe; Sepsis, Severe Sepsis and Septic Shock; Sepsis, Septic Shock; Sepsis With Acute Organ Dysfunction; Sepsis

Treatments: Genetic: RNA and DNA Sequencing

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT06809868

23-39420

Details and patient eligibility

About

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:

1. Do transposable elements prematurely age the immune systems of patients with sepsis?
2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU?
3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU?

Participants will have blood drawn from them but will not be subjected to additional interventions.

Enrollment: 116 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18 or older
• Admitted to ICU with sepsis (Sepsis 3 Criteria)
• SOFA score of at least 2 at time of enrollment

Exclusion criteria

• Patients on organ transplantation immunosuppression
• Patients with preexisting leukopenia
• Cancer patients receiving CAR-T therapy
• Patients who are under 18 years of age or otherwise deemed pediatric
• Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock)
• Patients with a chronic hemoglobin below 7.0
• Patients who, prior to their ICU admission, are blood transfusion dependent

Trial design

116 participants in 2 patient groups

Patients with Sepsis

Description:

Adult patients (age 18 and older) admitted to the intensive care unit (ICU) meeting Sepsis 3 Criteria.

Treatment:

Genetic: RNA and DNA Sequencing

Healthy Individual Controls

Description:

Healthy individuals not admitted to the hospital.

Treatment:

Genetic: RNA and DNA Sequencing